Stryker's modular dual mobility hip system gets FDA clearance
This article was originally published in Clinica
Executive Summary
MDM X3, a modular dual mobility mobile bearing hip system developed by Kalamazoo, Michigan-based Stryker's orthopaedics division, has received US 510(k) marketing clearance. MDM X3 is designed to address a broad patient population, including both primary and revision total hip arthroplasty candidates and those who may benefit from advanced fixation. The device follows on from Stryker's flagship mobile bearing product, ADM X3, which launched a year ago and contributed to Stryker's strong performance in the hip reconstruction market in 2010 (www.clinica.co.uk, 26 January 2011).
You may also be interested in...
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.